INTRODUCTION
============

MYH9-related diseases (MYH9-RD) are a spectrum of autosomal dominant (AD) disorders characterized by congenital thrombocytopenia, giant platelets and leucocyte inclusions named Döhle bodies. Additional extra-haematological manifestations can also occur, which are mainly hearing impairment, pre-senile cataract and nephropathy \[[@sfy117-B1]\].

May *et al*. in 1909 and Hegglin *et al*. in 1945 described, respectively, the leucocytic inclusions and their co-existence with giant platelets \[[@sfy117-B2], [@sfy117-B3]\]. In 1972, Epstein *et al*. \[[@sfy117-B4]\] reported two families with hereditary nephritis, deafness and macrothrombocytopenia. The description differed from Alport's syndrome by the severity of the disease in affected females and by the existence of macrothrombocytopenia. However, the patients presented with similar initial manifestations such as albuminuria and microhaematuria, which were followed by progressive renal deterioration. Thereafter, in 1985, one family with four generations was reported with nephritis, deafness, macrothrombocytopenia and cataract, associated with leucocytic inclusions that were not previously described by Esptein *et al*. The Fechtner syndrome was, therefore, defined as a novel variant of hereditary nephritis \[[@sfy117-B5]\]. Finally, the Sebastian syndrome was characterized in 1990 upon one family without any feature of Alport syndrome, but with hereditary macrothrombocytopenia and neutrophilic inclusions differing morphologically from those found in patients with the May--Hegglin disease \[[@sfy117-B6]\].

All these disorders appeared to be caused by mutations in the *MYH9* gene, which is present on chromosome 22q11--13 and encodes the non-muscle myosin heavy chain IIA (NMMHC-IIA) \[[@sfy117-B7], [@sfy117-B8]\]. The Class IIA non-muscle myosin is an ubiquitous hexameric motor protein consisting of two heavy chains and two pairs of light chains. It is implicated in spreading, cell motility, maintenance of cell morphological states and cytokinesis \[[@sfy117-B7]\].

Several studies suggest a genotype--phenotype correlation, with some of them displaying more aggressive features of the disease \[[@sfy117-B9]\]. These reports also reflect the highly inconstant existence and severity of kidney involvement \[[@sfy117-B1]\]. However, precise data concerning renal involvement in MYH9-RD are scarce with few renal series especially in Europe, and poor follow-up and data regarding the evolution of the disease.

This study focuses on the disease's evolution, renal and extra-renal presentation with documented genetic data of 13 patients among 9 families with a MYH9-RD and followed-up by nephrologists. The aim of the study was to demonstrate that renal involvement is greatly heterogeneous even between pedigrees and patients harbouring the same mutation.

MATERIALS AND METHODS
=====================

The study was approved by an independent protection committee of the North-West of France and conducted according to the declaration of Helsinki.

Patient selection
-----------------

We conducted a retrospective multicentre observational study and identified 13 patients among 9 families with *MYH9* mutation referred to nephrologists, before or after the diagnosis was confirmed by genetic testing ([Table 1](#sfy117-T1){ref-type="table"}).

###### 

Renal characteristics at referral to the nephrologist and at last follow-up

  Case    Age (years)   Proteinuria (g/day)      SCr (mg/dL)      eGFR (mL/min/1.73 m^2^)   Annual eGFR slope (mL/min/1.73 m^2^)   Hypertension   Haematuria
  ------ ------------- --------------------- ------------------- ------------------------- -------------------------------------- -------------- ------------
  1         26--54           0.95--0.5           1.03--1.35               69--43                            −0.9                       − +            −−
  2         76--78           3.1--0.5             1.11--5.7                51--8                           −21.5                       \+ +          \+ +
  3         18--52          \>3, anuria            1.3--HD                 76--0                           −12.7                       − +         − Anuria
  4         17--20          0.22--0.32            1.1--0.9                94--114                           +6.7                        −−            −−
  5         30--33           1.16--0.2            0.7--0.7               141--138                            −1                        − +            −−
  6         32--50          \>3, anuria        1--HD, deceased             90--0                             −5                        − +         − Anuria
  7         44--47            1.79--3         1.9--4, deceased            41--19                            −7.3                       \+ +          \+ +
  8         14--15          6.24--0.09        14--transplanted             4--0                                                        \+ +          \+ −
  9         21--23             3--1               1.1--1.06               90--92                             +1                        − −            −−
  10        64--69             0--0               1.2--1.3                44--41                             −1                        \+ +          \+ +
  11        44--47            1.5--0          1.5--transplanted            38--0                           −12.7                       \+ +           −−
  12        23--59            2.68--0         1.1--transplanted            66--0                            −1.8                       \+ −          \+ −
  13        35--39        \>3 (anuria)--0     5.6--transplanted        0 (anuria)--0                                                    −            \+ −

The first number in each column corresponds to what was found at the initial presentation, the second number to that of the last evaluation.

eGFR, estimated glomerular filtration rate; HD, haemodialysis.

Data collection
---------------

A standardized data collection protocol was subsequently formulated recording age, sex, mode of presentation, clinical characteristics, follow-up and genotype. The characteristic features of the disease were collected. Leucocytic inclusions and giant platelets were identified by May--Grünwald staining on a blood smear. Thrombocytopenia was defined as a platelet count \<150 × 10^9^/l. The glomerular filtration rate (GFR) was estimated by the Modification of Diet in Renal Disease equation. The renal biopsy was undergone according to standard technics. We specifically noted whether patients had developed end-stage renal disease (ESRD) and evaluated the progression of kidney disease. Hearing impairment was evaluated by audiogram and eye involvement by ophthalmologist assessment.

MYH9 disease diagnosis
----------------------

Abnormal NMMHC-IIA inclusions in the cytoplasm of neutrophils were assessed by immunofluorescent staining \[[@sfy117-B14]\] in the Department for platelet disorders (provided by N.S.) as well as the mutational screening on the *MYH9* gene.

Statistical analysis
--------------------

Data were described as counts and percent for categorical variables, and as mean and SD for continuous variables.

Results
=======

Family A
--------

### Patient 1

This patient was referred to a nephrologist at the age of 26 years with a 0.95 g/24 h proteinuria, whereas she was considered to have orthostatic proteinuria since the age of 14 years. Blood pressure was normal, urinary sediment was bland; estimated GFR (eGFR) was 69 mL/min/1.73 m^2^ with mild thrombocytopenia (102 000/mm^3^). She refused kidney biopsy. Since bone marrow aspiration was normal, a diagnosis of idiopathic thrombocytopenic purpura (ITP) associated with glomerulonephritis was made. Steroids were initiated without conclusive results. Renal function declined progressively, and nephrotic range proteinuria at the age of 45 years led to renin--angiotensin system (RAS) inhibitors initiation. After a follow-up of 28 years, eGFR was 43 mL/min/1.73 m^2^, proteinuria level was 0.95 g/24 h and blood pressure was normal on treatment.

### Patient 2

Patient 2 is the proband's mother. Chronic kidney disease (CKD) was diagnosed at 76 years old with eGFR and proteinuria at 51 mL/min/1.73 m^2^ and 3.1 g/24 h, respectively, microscopic haematuria and hypertension. Platelet count was low at 62 000/mm^3^. Two years later, she underwent a bone marrow aspirate because of pancytopenia, revealing a type 2 myelodysplastic syndrome. Shortly after the diagnosis of myelodysplasia, a neutropenic sepsis accelerated the decline of renal function towards ESRD.

### Patient 3

Patient 3 is the proband's brother. At the age of 18 years, he was hospitalized for a nephrotic syndrome with mild renal impairment (serum creatinine (SCr) level of 1.3 mg/dL). Kidney biopsy findings were consistent with focal segmental glomerulosclerosis (FSGS). The immunofluorescence evaluation was not available. Chronic vascular lesions were also reported with massive intimal fibrosis of arteries and arteriolar hyalinosis. The nephrotic syndrome proved to be resistant to steroids and then to a combination of steroids and cyclophosphamide (CPA). ESRD occurred 6 years later leading to haemodialysis at 24 and transplantation at 26 years of age. Of note, thrombocytopenia was intermittent with a normal platelet count (160 000/mm^3^) at initial presentation.

### Patient 4

Patient 4 is the proband's son. During a pre-operative check-up at 17 years old, peripheral thrombocytopenia at 50 000/mm^3^ was evidenced, without prior bleeding event or known thrombocytopenia at birth. A diagnosis of ITP led to steroids and intravenous immunoglobulins (IVIg) administration, which proved to be ineffective. At that time, kidney involvement was noticed, with proteinuria ranging from 0.2 to 0.5 g/24 h, SCr at 1.1 mg/dL and blood pressure was 144/82 mmHg. At the latest evaluation 3 years later proteinuria level was 0.32 g/24h, SCr 0.9 mg/dL and blood pressure remained normal without medication.

### MYH9-RD diagnosis

In 2009, when Patient 4 was diagnosed with thrombocytopenia and mild proteinuria, a hereditary syndrome was suspected. The pedigree chart ([Figure 1](#sfy117-F1){ref-type="fig"}) revealed an AD transmission and that the proband's grandfather had died of 'uraemia' at the age of 82 years. The association of glomerular nephropathy, thrombocytopenia and the family history led to suspicion of an MYH9-RD. Blood smears was performed in all members and revealed the presence of 3--5% of giant platelets but no Döhle bodies; neutrophilic inclusions were disclosed by immunofluorescence assay. Audiogram and ophthalmological tests were performed in all the members except Patient 3 and evidenced neurosensory hearing loss for the proband and her mother (Patients 1 and 2), but no cataract. Mutational screening of all the members of the family revealed a c.2152C\>T mutation on exon 16 predicting a p.R718W substitution on the mature protein.

![Pedigree chart of the Family A. Proband's (Patient 1) grandfather died at the age of 82 years of so-called 'uraemia'. The bottom right part of each box (in plain black) corresponds to renal involvement; the bottom left part (in fine stripes) to thrombocytopenia and the upper right part (in large stripes) to hearing disability.](sfy117f1){#sfy117-F1}

Characteristics of the rest of the cohort: one family, nine patients
--------------------------------------------------------------------

### At initial referral to the nephrologist

Median age was 32 years (range 14--64). Proteinuria was present in all patients but one (Patient 10), and Patient 6 was nephrotic at presentation. Haematuria and hypertension were both present in five patients out of nine. eGFR was \<60 mL/min/1.73 m^2^ in five patients ([Table 1](#sfy117-T1){ref-type="table"}). Patients 8 and 13 were referred to nephrologists without known urine abnormalities or CKD prior to admission. At initial evaluation, renal function was normal in Patient 8, and ESRD occurred 6 years later at the age of 15 years, without kidney function monitoring during this period. Acute renal failure secondary to cortical necrosis following post-partum haemorrhage did not recover for Patient 13. Eight out of nine patients had thrombocytopenia at presentation ranging from 4000 to 80 000/mm^3^, whereas patient 13 had a normal platelet count of 350 000/mm^3^ ([Table 2](#sfy117-T2){ref-type="table"}). Patients 11 and 13 had serious haemorrhagic events related to a post-partum haemorrhage and a ruptured spleen following a serious road accident, respectively. None of the other patients displayed even mild haemorrhagic or thrombotic events. Patients 11 and 12 had a history of cataract. Patient 11 was diagnosed with a Fuchs syndrome in childhood, and Patient 12 received surgery at the age of 47 years. Hearing loss was already diagnosed in three patients, and Patient 10 had a cochlear implant ([Table 3](#sfy117-T3){ref-type="table"}). Interestingly, seven patients had persistent but slight liver function abnormalities.

###### 

Haematological characteristics

  Case     Family     Pl count   Intermittent normal Pl count   Bleeding event   Leucocytes inclusions   Giant platelets
  ------ ----------- ---------- ------------------------------ ---------------- ----------------------- -----------------
  1       A probant    77 000                 −                       −                   \+                   \+
  2       A mother    103 000                 −                       −                    −                   \+
  3       A brother   160 000                 \+                      −                   \+                   \+
  4         A son      76 000                 −                       −                   \+                   \+
  5       B probant    40 000                 −                       −                   \+                   \+
  6       B father     80 000                 \+                      −                    ?                    ?
  7           −         9000                  −                       −                   \+                   \+
  8           −        53 000                 −                       −                   \+                   \+
  9           −         4000                  −                       −                   \+                   \+
  10          −        19 000                 −                       −                   \+                   \+
  11          −        60 000                 \+                      \+                  \+                   \+
  12          −        80 000                 −                       −                   \+                   \+
  13          −       350 000                 \+                      \+                  \+                   \+

The platelet count corresponds to that of the first referral to the nephrologist. Pl, platelet. Patient 11's bleeding event: road accident. Patient 13's bleeding event: post-partum haemorrhage. Pl Count per mm^3^.

###### 

General characteristics

  Case     Family     Gender       Mutation       Inheritance   Hearing impairment   Cataract   Liver enzymes increase
  ------ ----------- -------- ------------------ ------------- -------------------- ---------- ------------------------
  1       A probant     F          p.R718W            AD                \+              −                 −
  2       A mother      F          p.R718W            AD                \+              −                 \+
  3       A brother     M          p.R718W            AD                ?               ?                 \+
  4         A son       M          p.R718W            AD                −               −                 \+
  5       B probant     M          p.R1165C           AD                −               −                 −
  6       B father      M          p.R1165C           AD                ?               ?                 \+
  7           −         M          p.K74del           AD                \+              −                 \+
  8           −         F          p.D1424N           AD                −               −                 −
  9           −         M           p.S96L         Sporadic             \+              −                 \+
  10          −         F        Missing data         AD                \+              −                 −
  11          −         F          p.E894K         Sporadic             −               \+                −
  12          −         F      p.Q1070_A1087dup       AD                \+              \+                \+
  13          −         F          p.C2113T        Sporadic             −               −                 −

Predicted change in the mature protein based on genetic assessment of the mutations.

M, male; F, female; AD, autosomal dominant transmission.

Patients 3 and 6 did not undergo audiometry and eye examinations but neither of them had patent clinical symptoms consistent with hear or eye involvements. Ear and eye evaluations were carried out systematically.

### At the time of genetic testing

Genetic tests were performed following the occurrence of either new cases in relatives (Patients 5, 6 and 10) or of new symptoms (Patient 11 was initially followed for thrombocytopenia, and then presented with proteinuria and hypertension), or blood smears analysis revealing giant platelets and leucocyte inclusions (Cases 7, 8, 9, 12 and 13). Three patients (Cases 9, 11 and 13) were likely to have a *de novo* mutation since their relatives (parents and siblings) were tested for the mutation and were found negative. Mutations and mode of inheritance are listed in [Table 3](#sfy117-T3){ref-type="table"}.

Five out of nine patients were referred to the nephrologist without the diagnosis of MYH9-RD. Initial diagnosis, time to diagnosis and treatment are summarized in [Table 4](#sfy117-T4){ref-type="table"}. Time to MYH9-RD diagnosis was highly variable ranging from 0 to 19 years. The most common initial misdiagnoses were ITP (Patients 8 and 9) and other hereditary nephropathies, including Alport syndrome (Patients 5 and 12).

###### 

Initial diagnosis, treatment and time to diagnosis

  Case        Initial diagnosis              Treatment         Time to diagnosis (years)
  ------ ---------------------------- ----------------------- ---------------------------
  1       ITP and glomerulonephritis            CS                        23
  2         Hereditary nephropathy               0                         0
  3                  FSGS                     CS, CPA                     29
  4                  ITP                     CS, IVIg                      1
  5         Hereditary nephropathy               0                         2
  6           Glomerulonephritis                 0                        19
  7          May--Hegglin anomaly                0                         0
  8                  ITP                       IVIg                        5
  9                  ITP               CS, IVIg, splenectomy              10
  10         May--Hegglin anomaly                0                         0
  11           Thrombocytopenia                  0                        10
  12           Alport syndrome                   0                         3
  13          Cortical necrosis          Antifibrinolytics                 1

CPA, cyclophosphamide; CS, corticosteroids; FSGS, focal segmental glomerulosclerosis; ITP, idiopathicthrombocytopenic purpura; IVIg, intravenous immunoglobulins.

Seven mutations were identified, two located in the head domain (Patient 7: p.K74del and Patient 9: p.S96L) and five affecting the tail domain (Family B: p.R1165C, Patient 8: p.D1424N, Patient 11: p.E894K, Patient 12: p.Q1070_A1087dup and Patient 13: p.C2113T).

### At last evaluation

Renal characteristics are listed in [Table 1](#sfy117-T1){ref-type="table"}. Median follow-up by nephrologists was 3 years (range 1--34). Median annual eGFR change was −1.8 mL/min/1.73 m^2^ ranging from ±6.7 to −21.5 mL/min/1.73 m^2^. At the last evaluation of the four patients without ESRD, three of them had hypertension and were treated with RAS inhibitors, with variable proteinuria, ranging from 0 to 3 g/day. eGFR ranged from 19 to 138 mL/min/1.73 m^2^.

Five out of nine patients developed ESRD. Patients 8 and 13 were already in ESRD at the first evaluation by nephrologists. Patients 6, 11 and 12 developed ESRD, respectively, in 18, 3 and 36 years.

Patients 8, 11, 12 and 13 were transplanted at ages 15--46 years, with no haemorrhagic peri-operative complications. Patients 5 and 7 died at age 50 years from arrhythmia due to hyperkalaemia, and at 48 years old from a massive myocardial infarction, respectively.

DISCUSSION
==========

This series focuses on the characteristics of 13 individuals belonging to 9 families with genetically proven MYH9-RD. When first evaluated by a nephrologist, a majority of patients (10/13) presented with the association of thrombocytopenia and proteinuria, from mild proteinuria to nephrotic syndrome. Extra-renal features varied widely, with hearing impairment in six patients, cataract in two and mild liver dysfunction in seven. eGFR \<60 mL/min/1.73 m^2^, hypertension and haematuria were each present in six patients. Renal outcome was also highly unpredictable among patients and among families, with three patients developing a rapid onset ESRD whereas others, especially Patient 1, had a relatively stable kidney function over a long follow-up.

The prevalence of MYH9-RD is probably underestimated because of frequent misdiagnosis and underreporting \[[@sfy117-B1]\]. In particular, the knowledge of MYH9-RD among the nephrologist community is poor and mild thrombocytopenia could go unnoticed. Moreover, eye involvement could incorrectly be labelled as pre-senile cataract. These reasons could explain the frequent delay in diagnosis in our series. These misdiagnoses can lead to unnecessary treatments including aggressive therapies. In our study, ITP was an initial misdiagnosis in four patients, preceding from 1 to 23 years before MYH9 diagnosis, and leading to the administration of corticosteroids (CS), IVIgs and even a splenectomy in one patient, as in other published series \[[@sfy117-B12], [@sfy117-B13], [@sfy117-B15]\]. One of our patients was diagnosed as FSGS, consistently with literature \[[@sfy117-B16]\] ([Table 5](#sfy117-T5){ref-type="table"}), leading to potentially deleterious and inefficient treatments including CS and CPA.

###### 

Pathological findings in MYH9 syndrome

  References                               Age (years)  Sex    MYH9 mutation         SCr (mg/dL)          Proteinuria  Light microscopy                                                                                                       Electron microscopy
  --------------------------------------- ------------- ----- --------------- -------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Epstein *et al.* \[[@sfy117-B4]\]            13       F          R702C                 0.6               0.2 g/day   Segmental and global glomerulosclerosis, mesangial proliferation                                                       Not performed
  Clare *et al.* \[[@sfy117-B17]\]             15       M           ND                   1.2               14 g/day    Endocapillary proliferation, mesangial expansion, adhesions to Bowman\'s capsule, and moderate interstitial fibrosis   GBM thickening, lamellation
  Peterson *et al.* \[[@sfy117-B5]\]           23       M           ND                   ESRD                 \+       Preserved glomeruli with increased mesangial cell number and matrix                                                    GBM thickening, focal areas of attenuation; focal podocyte foot process effacement
  Túri *et al.* \[[@sfy117-B18]\]              14       M           ND                   0.8               1.6 g/day   Segmental glomerulosclerosis and diffuse mesangial proliferation                                                       Focal GBM thickening and splitting, foot process effacement
  Iyori *et al.* \[[@sfy117-B19]\]             14       F           ND                    NS                  \+       Mild tubular atrophy                                                                                                   Mesangial interposition, GBM splitting
  Moxey-Mims *et al.* \[[@sfy117-B20]\]         7       M           ND                   0.6               1.6 g/day   Mild mesangial expansion                                                                                               Mesangial cell proliferation and matrix expansion, GBM with variable thickening and basket-weave splitting
  Naito *et al.* \[[@sfy117-B21]\]             16       F           ND                    NS                  \+       Normal                                                                                                                 GBM thickening and reticulation of the lamina densa
  Naito *et al.* \[[@sfy117-B21]\]             12       F           ND                  Normal              2 g/day    Mesangial proliferation                                                                                                Partial splitting of GBM lamina densa
  Naito *et al.* \[[@sfy117-B21]\]             15       M           ND                    NS                  4+       Segmental glomerulosclerosis                                                                                           GBM thinning
  Ghiggeri *et al.* \[[@sfy117-B22]\]          49       M         D1424H                  5                   \+       Glomerulosclerosis                                                                                                     Non-specific
  Ghiggeri *et al.* \[[@sfy117-B22]\]          24       F         D1424H                  NS                  \+       Normal                                                                                                                 Focal segmental foot process effacement
  Alhindawi *et al.* \[[@sfy117-B23]\]         10       M           ND         eGFR 65 mL/min/1.73 m^2^       \+       Segmental and global glomerulosclerosis                                                                                Not performed
  Yap *et al.* \[[@sfy117-B24]\]               17       M          R702H                 2.3               4.5 g/day   Global glomerulosclerosis                                                                                              Not performed
  Sekine *et al.* \[[@sfy117-B12]\]             9       F          R702C                 0.4                  1+       Mild mesangial cell proliferation and expansion                                                                        Mesangial cell proliferation and matrix expansion, focal foot process effacement, focal GBM thickening
  Han *et al.* \[[@sfy117-B13]\]               28       M         D1424N                 0.8                  \+       FSGS                                                                                                                   Not performed
  Han *et al.* \[[@sfy117-B13]\]               22       M          S96L                   3                   \+       FSGS                                                                                                                   Focal GBM thickening
  Han *et al.* \[[@sfy117-B13]\]               1.2      M          S96L                  0.3                  \+       Mild mesangial expansion                                                                                               Focal GBM thickening
  Hao *et al.* \[[@sfy117-B25]\]               58       M         E1841K                 1.3              1.56 g/day   FSGS, IgM deposits                                                                                                     Not performed
  Sun *et al*. \[[@sfy117-B26]\]               43       M         E1945X               Abnormal               NS       FSGS, mesangial hyperplasia, matrix proliferation                                                                      Foot process fusion, microvillus hyperplasia
  Min *et al*. \[[@sfy117-B27]\]               11       F          C2104                Normal                \+       Diffuse proliferative mesangial glomerulonephritis                                                                     Not performed
  Min *et al*. \[[@sfy117-B27]\]               13       M          C287T                  NS                  \+       Diffuse proliferative mesangial glomerulonephritis                                                                     Not performed
  Oh *et al*. \[[@sfy117-B28]\]                14       F         E1841K                 0.7              0.96 g/day   4 glomeruli with global sclerosis out of 21, others normal                                                             Foot process effacement
  Present study                                18       M          R718W                 1.3               \>3 g/day   FSGS, intimal fibrosis of arteries, arteriolar hyalinosis                                                              Not performed

Pathological features of all the reported kidney biopsies, in our knowledge, of patients with an MYH9-RD diagnosis. Partly based on the review from Kopp \[[@sfy117-B16]\]. Predicted change in the mature protein based on genetic assessment of the mutations.

M, male; F, female; NS, not stated.

The spectrum of renal differential diagnosis is wide, depending on the detected symptoms. Proteinuria and pathological findings can lead to hereditary FSGS diagnosis. The main differential diagnosis is Alport syndrome, sharing the features of nephritis, cataract and sensorineural deafness, suspected in one of the patients of our study. Of note, microscopic haematuria consistent with Alport syndrome's renal features was present in five of our patients. Even though normal platelet counts do not exclude MYH9-RD \[[@sfy117-B1]\], the two syndromes can be differentiated by the most frequently X-linked inheritance of Alport syndrome, whereas MYH9-RD inheritance is AD. However, AD Alport disease is probably more frequent than first assumed and a non-negligible cause of hereditary FSGS \[[@sfy117-B29]\]. Its presentation can be misleading, with various but probably less severe phenotypes than X-linked Alport disease \[[@sfy117-B30]\]. Of note, previous ultrastructural analyses of kidney samples of MYH9-RD patients reported in [Table 5](#sfy117-T5){ref-type="table"} may reveal glomerular basement membrane (GBM) abnormalities suggestive of Alport syndrome, such as irregular thinning and thickening GBM with lamellated and basket-weave appearance \[[@sfy117-B12], [@sfy117-B16], [@sfy117-B22]\]. Extra-renal manifestations of MYH9-RD should thus be widely screened as well as family history. Even a moderate decrease in platelet count should lead to blood smears analysis. The diagnosis relies on the presence of immunofluorescent-positive NMMHC-IIA aggregates in neutrophils \[[@sfy117-B14]\] and genetic testing \[[@sfy117-B31]\].

Secondly, this study demonstrates that the severity of kidney involvement is heterogeneous, even within individuals harbouring the same mutation. Indeed, nephropathy occurs in 25--37% of patients with MYH9-RD according to the largest reported series \[[@sfy117-B9]\], with a variable age at onset. Pecci *et al*. have reported an overall rate of nephropathy per 100 person-year of 0.77 (95% CI 0.56--1.08). It usually presents with proteinuria, sometimes in the nephrotic range, with or without microhaematuria, leading to renal failure and eventually ESRD requiring renal replacement therapy in 43% of these patients according to the latter authors \[[@sfy117-B10]\].

In our study, the renal outcome was poorly predictable, whereas some patients presented with only mild proteinuria and stable eGFR during an overall median follow-up of 3 years, others rapidly evolved towards ESRD, even without nephrotic syndrome. Moreover, the onset of kidney disease may be late as in Patient 2, who was diagnosed at the age of 76 years. Noteworthy, the majority of family members of patients with a proven MYH9-RD had no kidney involvement. This incomplete penetrance underscores the need for regular renal examination including proteinuria, urinalysis and SCr in MYH9-RD patients and all family members.

The exact renal prognosis is thus largely unknown, and probably highly variable among patients with MYH9 mutations, even though genotype--phenotype correlations have been described \[[@sfy117-B10]\]. In previous reports as well as in our study, renal outcome was very heterogeneous and unpredictable \[[@sfy117-B4], [@sfy117-B5], [@sfy117-B12], [@sfy117-B13], [@sfy117-B15], [@sfy117-B19], [@sfy117-B24], [@sfy117-B27], [@sfy117-B28], [@sfy117-B32]\]. As shown in [Table 6](#sfy117-T6){ref-type="table"} listing available data on renal outcome from reported cases of MYH9 nephropathy, we cannot assert that usual prognostic factors of renal outcome (such as baseline eGFR, the degree of proteinuria and hypertension) are applicable in MYH9-RD.

###### 

Renal prognosis in reported cases of MYH9 nephropathy

  MYH9 nephropathy      First evaluation   Follow-up duration (years)   eGFR slope (mL/min/1.73 m^2^/year)   Last evaluation                                     
  -------------------- ------------------ ---------------------------- ------------------------------------ ----------------- ----------- ---------------------- ----------
  Non-ESRD (*n *=14)       22 (2--64)             86% (12/14)                       21% (3/14)                  1 (1--4)       3 (2--28)    −1 (−20.3 to 6.7)     3 (1--5)
  ESRD (*n *=29)           16 (1--76)             79% (23/29)                      35% (10/29)                  2 (1--5)       5 (0--23)   −12.7 (−21.5 to 1.8)      5

Data reported, when available, from all the reported cases of MYH9 nephropathy in our knowledge and our case series \[[@sfy117-B4], [@sfy117-B5], [@sfy117-B12], [@sfy117-B13], [@sfy117-B15], [@sfy117-B20], [@sfy117-B24], [@sfy117-B27], [@sfy117-B32]\]. Age, CKD stages, follow-up duration, eGFR slope are expressed in median (range) values. Proteinuria and hypertension are expressed in percentages (*N*/*n* total).

However, according to previous studies, it must be emphasized that renal pathological findings may have prognostic significance \[[@sfy117-B36], [@sfy117-B37]\]. For instance, Sekine *et al.* reported an MYH9-RD patient who underwent a kidney biopsy showing interstitial fibrosis and tubular atrophy, whereas eGFR was still normal, and subsequently developed ESRD 4 years later \[[@sfy117-B12]\].

Besides case reports, only two series have previously focused on renal involvement in MYH9-RD patients. Sekine *et al.* \[[@sfy117-B12]\] in the first one included nine unrelated patients with R702 mutations in the motor domain that all developed early proteinuria and four adult patients reached ESRD at the last evaluation \[[@sfy117-B12]\]. Han and colleagues reported seven unrelated patients with various mutations. Three patients demonstrating the most severe renal involvement were sporadic cases and had mutations in the motor domain, including one patient with the p.R718W substitution, like our study's Family A \[[@sfy117-B13]\].

According to previous studies, there was no overt bleeding diathesis, even in patients with the lowest level of platelets and in patients who received kidney biopsy or transplantation \[[@sfy117-B27]\]. This finding is consistent with earlier studies showing first, that the automated blood counters underestimate platelet rate since the large platelets of these patients are not taken into account \[[@sfy117-B38]\], and second, that these platelets display normal aggregation \[[@sfy117-B39], [@sfy117-B40]\]. Nonetheless, haemorrhage occurred in two patients following high bleeding risk events (road accident and post-partum bleeding). Transfusions of platelet concentrates and other therapies like desmopressin or eltrombopag \[[@sfy117-B41]\] can be used in the prevention and treatment of bleeding.

Cataract was a less frequent non-congenital feature of the disease, as has been reported in previous studies \[[@sfy117-B9]\]. It should be noted that hearing impairment was asymptomatic in our patients, and therefore should be systematically screened by a complete evaluation including audiogram. Noteworthy, altered liver profile was the most frequent extra-renal manifestation in our series in accordance with literature \[[@sfy117-B15], [@sfy117-B44]\]. This defect is not assumed to lead to liver disease but should rather provide an additional argument leading to MYH9-RD diagnosis.

Pathogenesis of nephropathy caused by MYH9 mutations is poorly known. NMII-A is expressed in podocytes and exerts an important regulation of cytoskeleton and cell migration \[[@sfy117-B45], [@sfy117-B46]\]. Consistently, it was reported that its expression was decreased in the glomerulus of patients with MYH9-RD and ultrastructural analysis of renal biopsies showed podocyte foot process effacement ([Table 5](#sfy117-T5){ref-type="table"}) \[[@sfy117-B12], [@sfy117-B16]\]. In experimental models, MYH9 podocyte-specific knockout in mice resulted in spontaneous glomerulosclerosis with foot process effacement and loss of the filtration slit membranes leading to proteinuria and eventually kidney failure \[[@sfy117-B45]\]. Furthermore, in Patient 3, FSGS was associated with unexpected severe intrarenal arterial and arteriolar lesions while the onset of the symptoms was recent and the patient was young without vascular history. These findings could be related to MYH9 expression in endothelial cells \[[@sfy117-B47]\], but to what extent MYH9 mutation could alter renal vasculature will need further research. Indeed, renal microvascular lesions have never been reported in humans and in mouse models of MYH9-RD \[[@sfy117-B48]\].

The position of mutations was initially thought to predict the severity of the phenotype. Mutations in the motor domain, allowing the mutant protein to copolymerize with wild-type NMMHC-IIA, might therefore have a dominant-negative effect, that is, a more severe phenotype \[[@sfy117-B11]\]. In contrast to this interpretation, Pecci *et al*. \[[@sfy117-B10]\] recently collected 255 MYH9-RD patients from 121 families and developed a model allowing prediction of the phenotype on the basis of the identified mutations. They found that all the motor domain mutations did not confer a severe prognosis. In our cohort, none of the patients harboured the mutations expected to be associated with the worse renal outcome, namely the one hitting the R702 residue and the p.D1424H substitution. Moreover, one of our patients with the most severe renal outcome (Patient 8) carried the p.D1424N substitution, known as a low-risk mutation \[[@sfy117-B10], [@sfy117-B11]\]. Hence, this study confirms the incomplete penetrance of nephropathy in MYH9-RD.

Our study has several limitations. First, it is a retrospective study with various follow-up durations. Secondly, only one patient underwent a kidney biopsy. Finally, two patients did not undergo systematic ear and eye evaluation during their follow-up. Despite these limitations, our study provides additional information on renal involvement in MYH9-RD with a long-term follow-up, pointing out inter- and intra-familial heterogeneity of the disease.

In conclusion, our study gathers 13 cases of MYH9-RD with kidney involvement and confirms the great heterogeneity in renal and extra-renal manifestations, even within the same family. The diagnosis of MYH9-RD is often delayed. It should be considered in any patient with a variable degree of glomerular involvement associated with a low or slightly decreased platelet count and/or hearing loss, cataract and liver dysfunction. Genetic testing will confirm the diagnosis after careful analysis of blood smear and immunofluorescence.
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